Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York. Show more
Location: One World Trade Center, New York, NY, 10007, United States | Website: https://www.axsome.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
5.188B
52 Wk Range
$75.56 - $139.13
Previous Close
$103.96
Open
$104.16
Volume
428,767
Day Range
$103.40 - $105.48
Enterprise Value
5.102B
Cash
303M
Avg Qtr Burn
-30.16M
Insider Ownership
16.09%
Institutional Own.
76.24%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AUVELITY [AXS-05] (NMDA receptor antagonist & sigma-1 agonist) Details Major depressive disorder | Approved Quarterly sales | |
Approved Quarterly sales | ||
Sunosi® (solriamfetol) Details Mental health, Excessive daytime sleepiness | Approved Quarterly sales | |
NDA Submission | ||
AXS-05 Details Alzheimer's disease | NDA Submission | |
Solriamfetol Details Shift work disorder | Phase 3 Data readout | |
Solriamfetol Details Binge eating disorder | Phase 3 Data readout | |
Solriamfetol Details Attention deficit hyperactivity disorder | Phase 3 Update | |
AXS-05 Details Alzheimer's disease | Phase 3 Update | |
Phase 3 Update | ||
Solriamfetol Details Major depressive disorder | Phase 3 Update | |
Solriamfetol Details Major depressive disorder with EDS | Phase 3 Initiation | |
Solriamfetol Details Attention deficit hyperactivity disorder (pediatric) | Phase 3 Initiation | |
AXS-05 Details Smoking cessation | Phase 2/3 Initiation |